Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 548086, 11 pages
http://dx.doi.org/10.1093/ecam/nep064
Review Article

The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III

1Immunosciences Lab., Inc., Los Angeles, CA 90035, USA
2NeuroScience, Inc., Osceola, WI 54020, USA

Received 28 November 2008; Accepted 22 May 2009

Copyright © 2011 Aristo Vojdani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-M. Gao and J.-S. Hong, “Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,” Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008. View at Publisher · View at Google Scholar · View at PubMed
  2. Y. Lampl, M. Boaz, R. Gilad et al., “Minocycline treatment in acute stroke: an open-label, evaluator-blinded study,” Neurology, vol. 69, no. 14, pp. 1404–1410, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. T. M. Tikka and J. E. Koistinaho, “Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia,” Journal of Immunology, vol. 166, no. 12, pp. 7527–7533, 2001. View at Google Scholar
  4. D. C. Wu, V. Jackson-Lewis, M. Vila et al., “Blockade of microglial activation is neuroprotective in the 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine administration,” Annals of Neurology, vol. 46, pp. 598–605, 2002. View at Google Scholar
  5. W. Zhang, T. Wang, L. Qin et al., “Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase,” FASEB Journal, vol. 18, no. 3, pp. 589–591, 2004. View at Google Scholar
  6. H. Kopf, G. M. de la Rosa, O. M. Z. Howard, and X. Chen, “Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells,” International Immunopharmacology, vol. 7, no. 13, pp. 1819–1824, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. G. R. Smith and S. Missailidis, “Cancer, inflammation and the AT1 and AT2 receptors,” Journal of Inflammation, vol. 1, article 3, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, and J. V. Ravetch, “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc,” Science, vol. 320, no. 5874, pp. 373–376, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. F. Nimmerjahn and J. V. Ravetch, “The antiinflammatory activity of IgG: the intravenous IgG paradox,” Journal of Experimental Medicine, vol. 204, no. 1, pp. 11–15, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. S. Fuchs, T. Feferman, R. Meidler et al., “A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis,” Journal of Neuroimmunology, vol. 194, no. 1-2, pp. 89–96, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. M. Feldmann and R. N. Maini, “TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases,” Nature Medicine, vol. 9, pp. 1245–1250, 2003. View at Google Scholar
  12. E. Tobinick, H. Gross, A. Weinberger, and H. Cohen, “TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study,” Medscape General Medicine, vol. 8, no. 2, article 25, 2006. View at Google Scholar
  13. B. E. Sands, F. H. Anderson, C. N. Bernstein et al., “Infliximab maintenance therapy for fistulizing Crohn's disease,” New England Journal of Medicine, vol. 350, no. 9, pp. 876–885, 2004. View at Publisher · View at Google Scholar · View at PubMed
  14. K. F. Croom and P. L. McCormack, “Adalimumab: in plaque psoriasis,” American Journal of Clinical Dermatology, vol. 10, no. 1, pp. 43–50, 2009. View at Publisher · View at Google Scholar
  15. P. Emery, J.-Y. Reginster, T. Appelboom et al., “WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis,” Rheumatology, vol. 40, pp. 699–702, 2001. View at Google Scholar
  16. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at PubMed
  17. M. Batten, J. Li, S. Yi et al., “Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells,” Nature Immunology, vol. 7, no. 9, pp. 929–936, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. S. K. Chauhan, J. El Annan, T. Ecoiffier et al., “Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression,” Journal of Immunology, vol. 182, no. 3, pp. 1247–1252, 2009. View at Google Scholar
  19. S.-C. Chun, S. Y. Jee, S. G. Lee, S. J. Park, J. R. Lee, and S. C. Kim, “Anti-inflammatory activity of the methanol extract of Moutan Cortex in LPS-activated Raw264.7 cells,” Evidence-Based Complementary and Alternative Medicine, vol. 4, no. 3, pp. 327–333, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. M. Wu and Z. Gu, “Screening of bioactive compounds from Moutan Cortex and their anti-inflammatory activities in rat synoviocytes,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 1, pp. 57–63, 2009. View at Publisher · View at Google Scholar · View at PubMed
  21. Y.-K. Yim, H. Lee, K.-E. Hong et al., “Anti-inflammatory and immune-regulatory effects of subcutaneous perillae fructus extract injections on OVA-induced asthma in mice,” Evidence-Based Complementary and Alternative Medicine, vol. 7, no. 1, pp. 79–86, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. Y. Liu, Z. Jia, L. Dong, R. Wang, and G. Qiu, “A randomized pilot study of atractylenolide I on gastric cancer cachexia patients,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 337–344, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. H. Chen, S. Shoumura, S. Emura, and H. Isono, “Tibetan medicated-bath therapy may improve adjuvant arthritis in rat,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 2, pp. 211–217, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. J. Y. Cho, S.-C. Park, T.-W. Kim et al., “Radical scavenging and anti-inflammatory activity of extracts from Opuntia humifusa Raf,” Journal of Pharmacy and Pharmacology, vol. 58, no. 1, pp. 113–119, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. J. Ao, H. Feng, and F. Xia, “Transforming growth factor and nuclear factor kappa B mediated prophylactic cardioprotection by total flavonoids of fructus chorspondiatis in myocardial ischemia,” Cardiovascular Drugs and Therapy, vol. 21, no. 4, pp. 235–241, 2007. View at Publisher · View at Google Scholar · View at PubMed
  26. J.-X. Wang, W. Tang, R. Zhou et al., “The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses,” British Journal of Pharmacology, vol. 153, no. 6, pp. 1303–1310, 2008. View at Publisher · View at Google Scholar · View at PubMed
  27. J.-Y. Tao, L. Zhao, Z.-J. Huang et al., “Anti-inflammatory effects of ethanol extract from Kummerowia striata (Thunb.) Schindl on LPS-stimulated RAW 264.7 cell,” Inflammation, vol. 31, no. 3, pp. 154–166, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. R. S. Talhouk, C. Karam, S. Fostok, W. El-Jouni, and E. K. Barbour, “Anti-inflammatory bioactivities in plant extracts,” Journal of Medicinal Food, vol. 10, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. C. H. Kim, “Regulation of FoxP3+ regulatory T cells and Th17 cells by retinoids,” Clinical and Developmental Immunology, vol. 2008, Article ID 416910, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. D. Mucida, Y. Park, G. Kim et al., “Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid,” Science, vol. 317, no. 5835, pp. 256–260, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. J. Mey, “Retinoic acid as a regulator of cytokine signaling after nerve injury,” Zeitschrift fur Naturforschung C, vol. 56, no. 3-4, pp. 163–176, 2001. View at Google Scholar
  32. Y. A. Taher, B. C. A. M. van Esch, G. A. Hofman, P. A. J. Henricks, and A. J. M. van Oosterhout, “1α,25-Dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-β1,” Journal of Immunology, vol. 180, no. 8, pp. 5211–5221, 2008. View at Google Scholar
  33. B. D. Mahon, S. A. Gordon, J. Cruz, F. Cosman, and M. T. Cantorna, “Cytokine profile in patients with multiple sclerosis following vitamin D supplementation,” Journal of Neuroimmunology, vol. 134, no. 1-2, pp. 128–132, 2003. View at Publisher · View at Google Scholar
  34. T. J. Wang, M. J. Pencina, S. L. Booth et al., “Vitamin D deficiency and risk of cardiovascular disease,” Circulation, vol. 117, no. 4, pp. 503–511, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. S. S. Harris, “Vitamin D in type 1 diabetes prevention,” Journal of Nutrition, vol. 135, no. 2, pp. 323–325, 2005. View at Google Scholar
  36. K. C. Chiu, A. Chu, V. L. W. Go, and M. F. Saad, “Hypovitaminosis D is associated with insulin resistance and β cell dysfunction,” American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 820–825, 2004. View at Google Scholar
  37. L. A. Merlino, J. Curtis, T. R. Mikuls, J. R. Cerhan, L. A. Criswell, and K. G. Saag, “Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study,” Arthritis and Rheumatism, vol. 50, no. 1, pp. 72–77, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. M. Cutolo, K. Otsa, M. Uprus, S. Paolino, and B. Seriolo, “Vitamin D in rheumatoid arthritis,” Autoimmunity Reviews, vol. 7, no. 1, pp. 59–64, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Cutolo and K. Otsa, “Review: vitamin D, immunity and lupus,” Lupus, vol. 17, no. 1, pp. 6–10, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. T. Li, G.-X. Fan, W. Wei, T. Li, and Y.-K. Yuan, “Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo,” International Immunopharmacology, vol. 7, pp. 1221–1231, 2007. View at Google Scholar
  42. A. M. Gonzales and R. A. Orlando, “Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes,” Nutrition and Metabolism, vol. 5, no. 1, pp. 17–30, 2008. View at Publisher · View at Google Scholar · View at PubMed
  43. P. Aebischer and A. C. Kato, “Playing defense against Lou Gehrig's disease,” Scientific American, vol. 297, no. 5, pp. 86–93, 2007. View at Google Scholar
  44. C. M. Galdeano, A. de Moreno de Le Blanc, G. Vinderola, M. E. B. Bonet, and G. Perdigon, “Proposed model: mechanisms of immunomodulation induced by probiotic bacteria,” Clinical and Vaccine Immunology, vol. 14, pp. 485–492, 2007. View at Google Scholar
  45. P. Pochard, P. Gosset, C. Grangette et al., “Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients,” Journal of Allergy and Clinical Immunology, vol. 110, no. 4, pp. 617–623, 2002. View at Publisher · View at Google Scholar
  46. S. Ménard, C. Candalh, J. C. Bambou, K. Terpend, N. Cerf-Bensussan, and M. Heyman, “Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport,” Gut, vol. 53, no. 6, pp. 821–828, 2004. View at Publisher · View at Google Scholar
  47. A. Ljungh and T. Wadström, “Lactic acid bacteria as probiotics,” Current Issues in Intestinal Microbiology, vol. 7, no. 2, pp. 73–90, 2006. View at Google Scholar
  48. L. V. McFarland, C. M. Surawicz, R. N. Greenberg et al., “A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease,” Journal of the American Medical Association, vol. 271, no. 24, pp. 1913–1918, 1994. View at Publisher · View at Google Scholar
  49. S. Kempe, H. Kestler, A. Lasar, and T. Wirth, “NF-κB controls the global proinflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program,” Nucleic Acids Research, vol. 33, pp. 5308–5316, 2005. View at Google Scholar
  50. A. Bierhaus, J. Wolf, M. Andrassy et al., “A mechanism converting psychosocial stress into mononuclear cell activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 1920–1925, 2003. View at Publisher · View at Google Scholar · View at PubMed
  51. R. Al-Sadi, D. Ye, K. Dokladny, and T. Y. Ma, “Mechanism of IL-lβ-induced increase in intestinal epithelial tight junction permeability,” Journal of Immunology, vol. 180, no. 8, pp. 5653–5661, 2008. View at Google Scholar
  52. S. Brandt, T. Kwok, R. Hartig, W. König, and S. Backert, “NF-κB activation and potentation of proinflammatory responses by the Helicobacter pylori CagA protein,” Proceedings of the National Academy of Sciences, vol. 102, pp. 9300–9305, 2005. View at Google Scholar
  53. J. Sun, X. D. Wang, H. Liu, and J. G. Xu, “Ketamine suppresses intestinal NF-kappaB activation and proinflammatory cytokines in endotoxic rats,” World Journal of Gastroenterology, vol. 10, pp. 1028–1031, 2004. View at Google Scholar
  54. K. Yoshizaki, T. Kuritani, and T. Kishimoto, “Interleukin-6 in autoimmune disorders,” Seminars in Immunology, vol. 4, no. 3, pp. 155–166, 1992. View at Google Scholar
  55. A. S. Brown, J. Hooton, C. A. Schaefer et al., “Elevated maternal interleukin-8 levels and risk of Schizophrenia in adult offspring,” American Journal of Psychiatry, vol. 161, no. 5, pp. 889–895, 2004. View at Publisher · View at Google Scholar
  56. N. Husan, U. S. Mashiat, Z. Toossi, S. Khan, J. Iobal, and N. Islam, “Allicin-induced suppression of Mycobacterium tuberculosis 85B mRNA in human monocytes,” Biochemical and Biophysical Research Communications, vol. 335, pp. 471–476, 2007. View at Google Scholar
  57. C. Guruvayoorappan and G. Kuttan, “Beta-carotene inhibits tumor-specific angiogenesis by altering the cytokine profile and inhibits the nuclear translocation of transcription factors in B16F-10 melanoma cells,” Integrative Cancer Therapies, vol. 6, pp. 258–270, 2007. View at Google Scholar
  58. A. L. Kasinski, Y. Du, S. L. Thomas et al., “Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis (2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin,” Molecular Pharmacology, vol. 74, pp. 654–661, 2008. View at Google Scholar
  59. P. A. Ruiz, A. Braune, G. Hölzlwimmer, L. Quintanilla-Fend, and D. Haller, “Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells,” Journal of Nutrition, vol. 137, pp. 1208–1215, 2007. View at Google Scholar
  60. Y. D. Jiang, J. Cao, Q. Z. Dong, and S. R. Wang, “Experimental study of anti-antherosclerosis potency by lyceum seed oil and its possible mechanism,” Zhong Yao Cai, vol. 30, pp. 372–377, 2007. View at Google Scholar
  61. J. Rajakangas, M. Misikangas, E. Päivärinta, and M. Mutanen, “Chemoprevention by white currant is mediated by the reduction of nuclear beta-catenin and NF-kappaB levels in Min mice adenomas,” European Journal of Nutrition, vol. 47, pp. 115–122, 2008. View at Google Scholar
  62. T. Syrovets, B. Büchele, C. Krauss, Y. Laumonnier, and T. Simmet, “Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinases,” Journal of Immunology, vol. 174, no. 1, pp. 498–506, 2005. View at Google Scholar
  63. L. Qian, S.-J. Wei, D. Zhang et al., “Potent anti-inflammatory and neuroprotective effects of TGF-β1 are mediated through the inhibition of erk and p47phox-Ser345 phosphorylation and translocation in microglia,” Journal of Immunology, vol. 181, no. 1, pp. 660–668, 2008. View at Google Scholar
  64. G. Monteleone, F. Pallone, and T. T. MacDonald, “Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses,” Trends in Immunology, vol. 29, no. 6, pp. 290–294, 2008. View at Publisher · View at Google Scholar · View at PubMed
  65. E. Volpe, N. Servant, R. Zollinger et al., “A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses,” Nature Immunology, vol. 9, no. 6, pp. 650–657, 2008. View at Publisher · View at Google Scholar · View at PubMed
  66. L. Zhou, J. E. Lopes, M. M. W. Chong et al., “TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function,” Nature, vol. 453, no. 7192, pp. 236–240, 2008. View at Publisher · View at Google Scholar · View at PubMed
  67. B. R. Conklin, E. C. Hsiao, S. Claeysen et al., “Engineering GPCR signaling pathways with RASSLs,” Nature Methods, vol. 5, no. 8, pp. 673–678, 2008. View at Publisher · View at Google Scholar · View at PubMed
  68. M. A. Febbraio and B. K. Pedersen, “Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?” Exercise and Sport Sciences Reviews, vol. 33, no. 3, pp. 114–119, 2005. View at Publisher · View at Google Scholar
  69. J. Gauldie, C. Richards, D. Harnish, P. Lansdorp, and H. Bauma, “Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, pp. 7251–7255, 1987. View at Google Scholar
  70. G. G. Wong and S. C. Clark, “Multiple actions of interleukin 6 within a cytokine network,” Immunology Today, vol. 9, no. 5, pp. 137–139, 1988. View at Google Scholar
  71. G. G. Wong, J. S. Witek-Giannotti, P. A. Temple et al., “Stimulation of murine hemopoietic colony formation by human IL-6,” Journal of Immunology, vol. 140, no. 9, pp. 3040–3044, 1988. View at Google Scholar
  72. Z. Walther, L. T. May, and P. B. Sehgal, “Transcriptional regulation of the interferon-β2/B cell differentiation factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines,” Journal of Immunology, vol. 140, no. 3, pp. 974–977, 1988. View at Google Scholar
  73. G. D. Roodman, N. Kurihara, Y. Ohsaki et al., “Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone,” Journal of Clinical Investigation, vol. 89, no. 1, pp. 46–52, 1992. View at Google Scholar
  74. K. Frei, U. V. Malipiero, T. P. Leist, R. M. Zinkernagel, M. E. Schwab, and A. Fontana, “On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases,” European Journal of Immunology, vol. 19, no. 4, pp. 689–694, 1989. View at Google Scholar
  75. T. Taga and T. Kishimoto, “Interleukin-6,” in Human Cytokines, B. B. Aggarwal and J. U. Gutterman, Eds., p. 143, Blackwell Scientific, Boston, Mass, USA, 1992. View at Google Scholar
  76. J. Guillermet-Guibert, N. Saint-Laurent, L. Davenne et al., “Novel synergistic mechanism for sst2 somatostatin and TNF-α receptors to induce apoptosis: crosstalk between NF-κB and JNK pathways,” Cell Death & Differentiation, vol. 14, pp. 197–208, 2007. View at Google Scholar
  77. Y. Chowers, L. Cahalon, M. Lahav et al., “Somatostatin through its specific receptor inhibits spontaneous and TNF-α-and bacteria-induced IL-8 and IL-1β secretion from intestinal epithelial cells,” Journal of Immunology, vol. 165, pp. 2955–2961, 2000. View at Google Scholar
  78. Y. Zavros, J. Y. Kao, and J. L. Merchant, “Inflammation and cancer III. Somatostatin and the innate immune system,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 286, no. 5, pp. G698–G701, 2004. View at Publisher · View at Google Scholar · View at PubMed
  79. H. Németh, H. Robotka, J. Toldi, and L. Vécsei, “Kynurenines in the central nervous system: recent developments,” Central Nervous System Agents in Medicinal Chemistry, vol. 7, no. 1, pp. 45–56, 2007. View at Publisher · View at Google Scholar
  80. R. Schwarcz and R. Pellicciari, “Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities,” Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 1, pp. 1–10, 2002. View at Publisher · View at Google Scholar · View at PubMed
  81. D. Hoyer, G. I. Bell, M. Berelowitz et al., “Classification and nomenclature of somatostatin receptors,” Trends in Pharmacological Sciences, vol. 16, no. 3, pp. 86–88, 1995. View at Publisher · View at Google Scholar
  82. Y. C. Patel, “Somatostatin and its receptor family,” Frontiers in Neuroendocrinology, vol. 20, no. 3, pp. 157–198, 1999. View at Publisher · View at Google Scholar · View at PubMed
  83. V. M. Sanders, “Interdisciplinary research: noradrenergic regulation of adaptive immunity,” Brain, Behavior, and Immunity, vol. 20, no. 1, pp. 1–8, 2006. View at Publisher · View at Google Scholar · View at PubMed
  84. W. Bondareff, C. Q. Mountjoy, M. Roth et al., “Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 1, no. 4, pp. 256–262, 1987. View at Google Scholar
  85. M. T. Heneka, E. Galea, V. Gavriluyk et al., “Noradrenergic depletion potentiates β-amyloid-induced cortical inflammation: implications for Alzheimer's disease,” Journal of Neuroscience, vol. 22, no. 7, pp. 2434–2442, 2002. View at Google Scholar
  86. A. P. Kohm and V. M. Sanders, “Norepinephrine and β2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo,” Pharmacological Reviews, vol. 53, no. 4, pp. 487–525, 2001. View at Google Scholar
  87. K. S. Madden, S. Y. Felten, D. L. Felten, P. R. Sundaresan, and S. Livnat, “Sympathetic neural modulation of the immune system. I. Depression of T cell immunity in vivo and in vitro following chemical sympathectomy,” Brain Behavior and Immunity, vol. 3, no. 1, pp. 72–89, 1989. View at Google Scholar
  88. R. C. Alaniz, S. A. Thomas, M. Perez-Melgosa et al., “Dopamine β-hydroxylase deficiency impairs cellular immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 2274–2278, 1999. View at Publisher · View at Google Scholar
  89. A. L. Mellor and D. H. Munn, “IDO expression by dendritic cells: tolerance and tryptophan catabolism,” Nature Reviews Immunology, vol. 4, no. 10, pp. 762–774, 2004. View at Publisher · View at Google Scholar · View at PubMed
  90. K. Färber, U. Pannasch, and H. Kettenmann, “Dopamine and noradrenaline control distinct functions in rodent microglial cells,” Molecular and Cellular Neuroscience, vol. 29, no. 1, pp. 128–138, 2005. View at Publisher · View at Google Scholar · View at PubMed
  91. Z. Li, J. A. Oben, S. Yang et al., “Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis,” Hepatology, vol. 40, no. 2, pp. 434–441, 2004. View at Publisher · View at Google Scholar · View at PubMed
  92. R. A. O'Connor, C. T. Prendergast, C. A. Sabatos et al., “Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 181, no. 6, pp. 3750–3754, 2008. View at Google Scholar
  93. S. Haak, A. L. Croxford, K. Kreymborg et al., “IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice,” Journal of Clinical Investigation, vol. 119, no. 1, pp. 61–69, 2009. View at Publisher · View at Google Scholar · View at PubMed
  94. C. B. Wilson, E. Rowell, and M. Sekimata, “Epigenetic control of T-helper-cell differentiation,” Nature Reviews Immunology, vol. 9, no. 2, pp. 91–105, 2009. View at Publisher · View at Google Scholar · View at PubMed
  95. C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harrington, “IL-17 family cytokines and the expanding diversity of effector T cell lineages,” Annual Review of Immunology, vol. 25, pp. 821–852, 2007. View at Publisher · View at Google Scholar · View at PubMed
  96. E. Bettelli, M. Oukka, and V. K. Kuchroo, “TH-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. S. C. Liang, X.-Y. Tan, D. P. Luxenberg et al., “Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides,” Journal of Experimental Medicine, vol. 203, no. 10, pp. 2271–2279, 2006. View at Publisher · View at Google Scholar · View at PubMed
  98. C. Dong, “TH17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews Immunology, vol. 8, pp. 337–348, 2008. View at Google Scholar
  99. J. J. Yu, M. J. Ruddy, H. R. Conti, K. Boonanantanasarn, and S. L. Gaffen, “The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis -induced periodontal bone loss,” Infection and Immunity, vol. 76, no. 9, pp. 4206–4213, 2008. View at Publisher · View at Google Scholar · View at PubMed
  100. M. W. Taylor and G. Feng, “Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism,” FASEB Journal, vol. 5, no. 11, pp. 2516–2522, 1991. View at Google Scholar